RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease
This study has been terminated.
Sponsor:
Repligen Corporation
Information provided by:
Repligen Corporation
ClinicalTrials.gov Identifier:
NCT00060515
First received: May 7, 2003
Last updated: August 4, 2005
Last verified: August 2005
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.
| Condition | Intervention | Phase |
|---|---|---|
|
Mitochondrial Diseases |
Drug: RG2133 (2',3',5'-tri-O-acetyluridine) |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Primary Purpose: Treatment |
| Official Title: | An Open-Label Dose-Escalation Phase I Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RG2133 (2',3',5'-Tri-O-Acetyluridine) in the Treatment of Inherited Mitochondrial Diseases |
Resource links provided by NLM:
Genetics Home Reference related topics:
ataxia neuropathy spectrum
childhood myocerebrohepatopathy spectrum
deoxyguanosine kinase deficiency
mitochondrial neurogastrointestinal encephalopathy disease
myoclonic epilepsy myopathy sensory ataxia
U.S. FDA Resources
Further study details as provided by Repligen Corporation:
Eligibility| Ages Eligible for Study: | 3 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Mitochondrial Disease
Contacts and Locations
No Contacts or Locations Provided
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00060515 History of Changes |
| Other Study ID Numbers: | RG2133-01 |
| Study First Received: | May 7, 2003 |
| Last Updated: | August 4, 2005 |
| Health Authority: | United States: Food and Drug Administration |
Additional relevant MeSH terms:
|
Mitochondrial Diseases Metabolic Diseases |
ClinicalTrials.gov processed this record on May 19, 2013